Patricia Danzon - OHE

We found for

Capturing the Broader Value of Antibiotics

Read more

NICE enough? Do NICE’s Decision Outcomes Impact International HTA Decision-making?

Read more

Incentivising New Antibiotics: Designing a Value-Based Delinked Pull Incentive Mechanism

Read more

Eye-Disease Gene-Therapies blog

Insight
February 2023

Cost-effectiveness Analysis of Gene Therapies for Inherited Eye Disease: Are Current Discounting Approaches Too Short-sighted?

Digital Health

Navigating the Landscape of Digital Health – United Kingdom

Read more

Blog 4

Insight
October 2022

The Economics of Antibiotics – Part 4: What Does the Antibiotics Market of the Future Look Like?

Insight
October 2022

The Economics of Antibiotics – Part 3: Creating a Healthy Global Market for New Antibiotics

Insight
October 2022

The Economics of Antibiotics – Part 2: Value Assessment within the NICE-NHS AMR Pilot

Insight
October 2022

The Economics of Antibiotics – Part 1: Why NICE and NHS England are Testing an Innovative HTA and Payment Model to Tackle Antimicrobial Resistance

The Value of Vaccines in Maintaining Health System Capacity in England

Read more

Realising The Broader Value of Vaccines in the UK: Ready for Prime Time?

Read more

© Mitrovix

The Broader Value of Vaccines: The Return on Investment From a Governmental Perspective

Read more

Health Technology Assessment…

Realising the Broader Value of Vaccines in the UK

Read more

Delivering the 2.4 Percent: Unlocking UK Pharma R&D Investment through Evidence-Based Policies

Read more

The WHO Technical Report on the Pricing of Cancer Medicines: Missing a central role for HTA and value assessment

Read more

Pharmaceutical Pricing in Europe: Is Differential Pricing a Win-Win Solution?

Read more